Cytomos
Generated by Meeveem AI
"Predictive cell analysis that transforms bioprocessing decisions in real time"
Edinburgh
•11 - 50 Employees
•Medical Devices
About Cytomos
Cytomos develops AuraCyt, a dielectric spectroscopy technology that measures intrinsic cell properties without labels or complex assays. The flagship platform, Celledonia, generates digital fingerprints of individual cells, predicting cell health, productivity, and quality in real time. This enables bioprocessing teams to make confident, data driven decisions that accelerate development and optimise manufacturing. The technology serves biopharmaceutical companies, cell and gene therapy developers, and research laboratories. By eliminating delays between analysis and action, Cytomos empowers scientists to streamline workflows, reduce costs, and bring precision medicines to market faster, supporting the lifecycle of biologic therapies.
30
Team Members
2011
Founded
Medical Devices
Sector
On-Site
Work Environment
Our Vision
A world where every cell's potential is understood, enabling the development of life saving therapies without delay or uncertainty.
Our Mission
Cytomos empowers bioprocessing teams with real time, predictive cell analytics that accelerate discovery, streamline manufacturing, and bring precision therapies to patients faster.